Cancer Health Fall Issue

A movement toward a greater focus on patient-reported outcomes is afoot.

High-tech approach solves ‘real mystery’ in many cancers.

A new classification system may more accurately reflect liver-related death trends in the United States.

Checkpoint inhibitor combination led to higher response rates and longer survival than Opdivo alone.

“Our goal is to identify risk factors that can predict or mitigate the risk of these people developing second primary cancers.”

The story of Thanksgiving is one of struggle, learning, survival, and perseverance.

Sexual side effects are a common after various cancer treatments, including those for prostate, bladder and colon cancers.

Prescribing a medicine for a purpose not approved by the FDA is legal and common. It sometimes leads to new and effective uses of a drug.

People with liver cirrhosis often have substantial financial burden that interferes with their care.